The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.
|Articles|August 28, 2014
- Head and Neck Cancers (Issue 1)
- Volume 1
- Issue 1
Immunotherapy in Head and Neck Cancers
Author(s)Ezra Cohen, MD
Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses immunotherapy in head and neck cancer.
Advertisement
Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses immunotherapy in head and neck cancer.
View more about novel approaches to the treatment of head and neck cancers > >
Articles in this issue
about 12 years ago
Unmet Needs in the Treatment of Thyroid Cancerabout 12 years ago
Molecular Markers Emerge in the Diagnosis of Thyroid Cancerabout 12 years ago
Results of the SELECT Trial in Thyroid Cancerabout 12 years ago
Update on Targeted Therapies in Head and Neck Cancersabout 12 years ago
Multidisciplinary Approach to Head and Neck Cancers May Improve OutcomesAdvertisement
Related to this article
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5